- Unlearn’s Series C Funding Achievement: Unlearn secures $50M Series C led by Altimeter Capital, with contributions from Radical Ventures, Wittington Ventures, Mubadala Capital, among others, to advance AI in clinical trials.
- Innovative Digital Twins Technology: Unlearn’s AI creates digital twins for trial participants, enabling more efficient, smaller trials by predicting health outcomes, thereby accelerating drug and therapy development.
- Regulatory Milestones and Expansion: Gained qualification from the European Medicines Agency and agreement from the FDA, with plans to expand into more therapeutic areas and invest in R&D.
Eksentricity 